5395232025-04-012025-06-305395232025-04-012025-06-30in-capmkt:OtherExpenses1Member5395232025-04-012025-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5395232025-04-012025-06-30

ItemsThatWillBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

539523

ALKEM

NOTLISTED

INE540L01014

ALKEM LABORATORIES LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-08-12

2025-08-04

INR

Millions

Quarterly

First quarter

Single segment

The Company is exclusively engaged in pharmaceutical business

2025-08-12

11:00:00

2025-08-12

13:25:00

Not applicable

2025-04-01

2025-06-30

Unaudited

Consolidated

33711400000

1364900000

35076300000

8271100000

3972000000

-531500000

6932500000

297800000

876800000

7676800000

27495500000

7580800000

129300000

7710100000

1411100000

-384200000

1026900000

6683200000

-4100000

6679100000

20800000

6699900000

6642600000

36500000

23100000

-2300000

239100000

55.56

1. The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI LODR Regulations 2015. 2. The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 11 August 2025 and subsequently approved by the Board of Directors at its meeting held on 12 August 2025. The auditors have issued an unmodified review report on the financial results for the quarter ended 30 June 2025. 3.The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year. 4.The comparative financial results of the Group for the quarter ended 30 June 2024 prepared in accordance with Ind AS included in this statement have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial results is dated 9 August 2024. 5.The Group has made the following acquisitions in wholly owned subsidiaries during the quarter ended 30 June 2025: a. 100% stake in Adroit Biomed Limited, on 23 April 2025 for a total consideration of Rs 1400 Million subject to conditions in the agreement. b. 100% stake in Bombay Ortho Industries Private Limited on 16 April 2025 through its wholly owned subsidiary Alkem Medtech Private Limited for a total consideration of Rs 1470 Million subject to conditions in the agreement. The said acquisitions do not have any material impact on the results for the quarter ended 30 June 2025. 6.Exceptional items for the quarter ended 30 June 2025 primarily includes: a. Gain of Rs 142.9 million from the sale of Indore facility classified as held for sale in the previous year and sold in the current period in accordance with the business transfer agreement entered with the buyer. 7. The Group operates in one reportable business segment i.e. Pharmaceuticals, accordingly no separate disclosure of segment information has been made.

Other Expenses

7676800000

Remeasurements of defined benefit plans

-47600000

-2900000

Foreign currency translation difference of foreign operations

65500000

20800000